Compare MasTec Inc (MTZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs State Street SPDR S&P Biotech ETF — how do they compare? MasTec Inc trades at $212.75 (market cap $17.40B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: MasTec Inc is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MTZ | XBI | |
|---|---|---|
Market Cap | $17.40B | $10.11B |
Volume | 1,415,821 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $437.51 | $169.55 |
52-Week Low | $190.08 | $104.99 |
Typical Hold Time | 23 Days | 38 Days |
Enterprise Value | $20.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $212.65, down 4.8% amid bearish technical signals, though recent earnings show mixed results with two beats and one miss. The company maintains strong analyst support with 88.9% buy ratings and a $408.58 consensus target, supported by record $21.4B backlog and infrastructure demand growth. Revenue reached $14.3B in 2025 with 3.07% net margin, while valuation ratios appear elevated with P/E of 34.5.
MTZ presents a compelling infrastructure growth story with AI and data center exposure, though premium valuation and weak cash flow pose near-term risks. The stock's current discount to analyst targets offers potential upside if execution improves, but investors should monitor communications segment softness and margin pressures in a competitive contracting environment.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
